2/3rds of US Adults Live With Chronic Disease – Theirs or Loved One
March 24, 2010 
1 Comment
One Response to “2/3rds of US Adults Live With Chronic Disease – Theirs or Loved One”
Leave a reply to Dan Jacome Cancel reply
Share This
My LinkedIn Profile
WSJ Health Blog
- Is a Paleo Diet Healthier Than Standard Nutritional Guidelines?
- Small Business and the Affordable Care Act: How Has Your Business Been Affected?
- HealthCare.gov Explorer: Decode the Health Law’s Subsidies
- One Reporter, Four Families, Six Scientists and the Search to Cure a Rare Disease
- Your Responses: How Has the Health Law Affected You?
- What Does the Health Law Mean for You? Your Questions Answered
- How Has the Health Law Affected You?
- Rare Diseases and the Search for a Cure: A Reddit AMA
- Robots to Cure Rare Diseases: A Reddit Ask Me Anything (AMA)
- Six Tips For Better Napping
Drug Channels
- Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026
- 340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)
- 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth
- Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low (rerun)
- The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices (rerun)
- Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)
- Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies (rerun)
- How Large PBMs Make Money Today: A 2025 Drug Channels Update (rerun)
- Closing the Specialty Access Gap: How GoodRx Turns Intent Into Therapy Starts
- List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs
KevinMD Blog
- An error has occurred; the feed is probably down. Try again later.
Health Populi
- The New Health Consumer Mindset and Wallet: From GLP-1s to Trading Up for Health & Longevity
- Men’s Fertility Feelings – The Influence of Trust and Social Media (My Progyny Post #3)
- Trust and AI in Healthcare: At a Crossroads, Edelman Finds
- A Month Until #CES2026 – The Journey to Our Personal Health Operating Systems
- The Home Economics of Family and Fertility: Men’s Financial Views on Their Fertility Journeys (My Progyny Post #2)
- Giving Thanks for Pinksocks Today and Every Day….celebrating the book!
- Feeling Under-Served and Overlooked: Men’s Views on Their Fertility Journeys (My Progyny Post #1)
- Where Health Meets Beauty, Mental Health, and Faith: Learning from the Farmaceutica di Santa Maria Novella
- As SNAP Benefits Were Threatened to be Cut in the U.S., Eli Lilly’s Obesity Drugs Rose to the World’s Best-Selling Drug
- The Real Face of Men’s Health in America: Years of Life Lost, Yearning for Social Connection, and Eroding Trust in Health Care
e-Patients
- Collaboration is the Best Medicine: Patient-Centered Collaboration Grounded in Caritas®
- Collaboration is the Best Medicine: It’s the Heart of Caregiving
- Collaboration is the Best Medicine: How to Partner with Your Doctor for Better Care
- Collaboration is the Best Medicine: Bridging the Gap in Patient Participation
- Dealing with Medical Uncertainty, Ambiguity, and Frustration
- Collaboration is the Best Medicine: The Time for Participatory Medicine is Now
- In Memory of Nancy Finn: e-Patient, Advocate, Author, SPM Supporter
- A cure for what killed Doc Tom! Can people afford it?
- Learning Health Systems Empower Every American to Actually Make America Healthy Again Together, Part 2
- Learning Health Systems Empower Every American to Actually Make America Healthy Again Together, Part 1
Enabling Healthy Decisions Blog by www.georgevanantwerp.com is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.
Contact Information
Contact me at gvanantwerp @ mac.com.
Enabling Healthy Decisions 
good for stocks like HWAY, IMA, and ALLI – obamacare should lead to a long term uptick in volumes for them, possibly. PBMs should win, too – given that chronic disease reflects 95%+ of drug spend, right?